-
2024-516083-28-00
10
2022-06-01
Prostate cancer
-
2023-506081-31-00
5
2022-03-29
Traumatic Injury
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-517854-91-00
5
2019-08-05
Metastatic or high-risk recurrent prostate cancer managed with androge
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-519516-14-01
4
2019-04-15
Metastatic prostate cancer, Prostate cancer
-
2024-515350-25-01
6
2019-04-12
Acute wheezing/bronchiolitis
-
2024-516320-33-00
5
2019-01-07
Bladder cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-517488-22-00
6
2018-05-28
Patients in high risk for infantile spasm syndrome (age under 1 yr old
-
2024-517236-22-00
5
2017-09-20
Intradural saccular unruptured aneurysm
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2025-525059-23-00
3
2026-03-04
healthy volunteers
-
2024-519743-15-00
5
2025-10-20
Influenza immunisation
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis